Physician profile
Maria Trirogoff
NPI 1033266911
$3,079.10
in general payments reported to CMS, 2019-2025
23 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $373 · 2021: $336 · 2022: $467 · 2023: $689 · 2024: $264 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $763.09 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $463.85 | 2019-2024 | Veltassa |
| Amgen INC. | $297.37 | 2019-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $256.34 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $143.15 | 2020-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $132.96 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $132.30 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $118.78 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $101.04 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $88.56 | 2019 | |
| Aurinia Pharma U.S., INC. | $85.18 | 2021-2023 | Lupkynis |
| Fresenius USA Marketing, INC. | $69.89 | 2019-2025 | Velphoro |
| Medtronic, INC. | $68.41 | 2023 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $64.22 | 2021-2023 | Benlysta |
| Veloxis Pharmaceuticals, INC. | $58.73 | 2024-2025 | Envarsus |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $51.69 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $48.17 | 2023 | |
| Alexion Pharmaceuticals, INC. | $47.81 | 2019 | |
| Nxstage Medical, INC. | $24.73 | 2023 | Nxstage System One |
| Genentech USA, INC. | $19.88 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.89 | 2019 | |
| Scpharmaceuticals INC. | $14.62 | 2025 | |
| Merck Sharp & Dohme LLC | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Trirogoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.